Reports Q2 revenue $24.72M, consensus $13.88M. “In recent months, we have continued to advance our innovative Probody(R) Therapeutic pipeline, while making significant progress with our partners across a wide range of programs and therapeutic modalities,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. “With a recent strategic financing completed with long-term CytomX shareholder, BVF Partners, we have strengthened our financial position and extended our cash runway into the second half of 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTMX:
- CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- CTMX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
- CytomX Therapeutics Announces New Employment Inducement Grants
- CytomX Therapeutics announces new employment inducement grants